Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 8/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2212218 | 1.00 | HSD11B1 (0.47) | HSD11B1HRH3NPY5RCYP2D6LMNA | |
| SCHEMBL12511832 | 1.00 | HSD11B1 (0.47) | HSD11B1HRH3NPY5RCYP2D6LMNA | |
| SCHEMBL4980523 | 0.77 | MEN1 (0.43) | HSD11B1LMNATSHR | |
| SCHEMBL13462295 | 0.77 | HSD11B1 (0.46) | HSD11B1 | |
| SCHEMBL2212786 | 0.72 | AVPR1A (0.53) | HSD11B1HRH3NPY5RLMNAAVPR1A | |
| SCHEMBL4554348 | 0.71 | HSD11B1 (0.57) | HSD11B1CYP2D6 | |
| SCHEMBL2209014 | 0.70 | AVPR1A (0.53) | HSD11B1HRH3NPY5RLMNAAVPR1A | |
| SCHEMBL2212186 | 0.70 | HSD11B1 (0.55) | HSD11B1 | |
| SCHEMBL6873588 | 0.68 | SIGMAR1 (0.60) | — | |
| Hydrochloric Acid SCHEMBL6880643 | 0.65 | SIGMAR1 (0.36) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678806-B2 | Spiro-piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-7501432-B2 | Spiro-piperidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7495008-B2 | Spiro-piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-20080280898-A1 | Spiro-piperidine derivatives | HOFFMANN-LA ROCHE, INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080167333-A1 | NEW SOLID FORMS OF [4-(3-FLUORO-5-TRIFLUOROMETHYL-PYRIDIN-2-YL)-PIPERAZIN-1-YL-[5-METHANESULFONYL-2-((S)-2,2,2-TRIFLUORO-1-METHYL-ETHOXY)-PHENYL]-METHANONE | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2008-07-10 | — | — | US | disclosed |
| US-20080161304-A1 | Spiro-piperidine derivatives | HOFFMANN-LA ROCHE, INC. | 2008-07-03 | — | — | US | disclosed |
| WO-2008077811-A1 | SPIRO-PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161304-A1 | Spiro-piperidine derivatives | AVPR1A, AVPR1B, ADRA1A | HSD11B1 1386/4885HRH3 433/4885NPY5R 53/4885 |
| US-20080167333-A1 | NEW SOLID FORMS OF [4-(3-FLUORO-5-TRIFLUOROMETHYL-PYRIDIN-2-YL)-PIPERAZIN-1-YL-[5-METHANESULFONYL-2-((S)-2,2,2-TRIFLUORO-1-METHYL-ETHOXY)-PHENYL]-METHANONE | HTR1A, HTR5A, ADRA1A | HSD11B1 1815/4885HRH3 340/4885NPY5R 21/4885 |
| US-20080280898-A1 | Spiro-piperidine derivatives | AVPR1A, AVPR1B, ADRA1A | HSD11B1 1386/4885HRH3 433/4885NPY5R 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.